Auriga Reaffirms Buy Rating on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals traded down 0.59% on Wednesday, hitting $49.28. Jazz Pharmaceuticals has a 52-week low of $26.17 and a 52-week high of $54.50. The company has a market cap of $2.657 billion and a price-to-earnings ratio of 18.90.
Jazz Pharmaceuticals last posted its quarterly earnings results on Tuesday, May 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.01. The company’s revenue for the quarter was up 113.0% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals will post $1.30 EPS next quarter.
A number of other analysts have also recently weighed in on JAZZ. Analysts at Mizuho raised their price target on shares of Jazz Pharmaceuticals from $62.00 to $75.00 in a research note to investors on Wednesday, May 2nd. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of Jazz Pharmaceuticals in a research note to investors on Friday, April 13rd. They set an “outperform” rating on the stock. Finally, analysts at Citigroup (NYSE: C) initiated coverage on shares of Jazz Pharmaceuticals in a research note to investors on Tuesday, April 10th. They set a “buy” rating and a $60.00 price target on the stock.
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.